Navigation Links
Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
Date:5/30/2008

ngle agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) with cytarabine in acute myelogenous leukemia, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, particularly Cloretazine(R) (VNP40101M), delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies, clinical trials or interim clinical trial data are not predictive of safety and efficacy results in later or final clinical trials, the need for additional research and testing, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, the possible delisting of the Company's common stock from the NASDAQ Capital Market and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2007 and Form 10-Q for the quarter ended March 31, 2008. In particula
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
2. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
3. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
4. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
5. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
6. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
7. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
8. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
9. Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
10. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
11. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... -- Repeated exposure to broad-spectrum antibiotics in the first two ... say researchers from The Children,s Hospital of ... data from electronic health records from the extensive CHOP ... children with four or more exposures to broad spectrum ... at risk for obesity. The study, published online September ...
(Date:9/29/2014)... Pharmacists have an important role in ... good clinical trials practices. The Hematology/Oncology Pharmacy Association ... Practice Standards, the first of its kind that ... pharmacists and institutions that conduct clinical trials. The ... the critical role of the pharmacist in the ...
(Date:9/29/2014)... NEW YORK , Sept. 29, 2014 ... Summary GlobalData,s new report, "EU5 ... market data on the EU5 Capsule Endoscopy Systems market. ... volume (in units) and average prices (in US dollars) ... Recorders and Capsule Endoscopy Workstations. The report ...
Breaking Medicine Technology:Antibiotic Use by Age 2 Associated with Obesity Risk 2Antibiotic Use by Age 2 Associated with Obesity Risk 3HOPA Introduces First Investigational Drug Service Best Practice Standards For Institutions And Infusion Clinics 2HOPA Introduces First Investigational Drug Service Best Practice Standards For Institutions And Infusion Clinics 3EU5 Capsule Endoscopy Systems Market Outlook to 2020 2EU5 Capsule Endoscopy Systems Market Outlook to 2020 3
... and Company (NYSE: LLY ) announced the ... Committee voted today to recommend non-approval of liprotamase, a ... review for the treatment of exocrine pancreatic insufficiency (EPI). ... questions about the degree of efficacy of liprotamase and ...
... gloStream, maker of gloEMR and gloPM – the only ... software with Microsoft Office built right in – today announced ... the gloEMR product line. Like its predecessor versions, gloEMR 6.0 ... platform, SQL Server and Microsoft Office so users have access ...
Cached Medicine Technology:Statement From Lilly on FDA Advisory Committee Recommendation Regarding Liprotamase New Drug Application for Treatment of Exocrine Pancreatic Insufficiency 2gloStream Announces Release of Microsoft-Based, Meaningful Use Certified gloEMR 6.0 2gloStream Announces Release of Microsoft-Based, Meaningful Use Certified gloEMR 6.0 3
(Date:9/30/2014)... California (PRWEB) September 30, 2014 The ... to reach USD 38.75 billion by 2020 at an ... to a new study by Grand View Research, Inc. ... due to lifestyle habits such as excessive alcohol consumption ... organ failure rates is expected to serve this market ...
(Date:9/30/2014)... AxoGen, Inc. (NASDAQ: AXGN), a ... repair market, announced the presentation of clinical data for ... Surgery of the Hand (ASSH) 2014 Annual Meeting which ... , The ASSH Best Paper Award was given to ... for Large Gap Nerve Discontinuities: Outcomes From a National ...
(Date:9/30/2014)... World of Children Award ( http://www.worldofchildren.org ... nonprofit, Friends Without A Border (FWAB) – in New ... hospital in Cambodia that has become the nation’s model ... Cambodia’s appalling lack of pediatric healthcare when he met ... during a photography trip in 1993. , Horrified, Izu ...
(Date:9/30/2014)... Farmington, NY (PRWEB) September 30, 2014 Timber ... design/build process for the Olsen family’s reclaimed Douglas fir ... will cover the home’s journey from architectural planning, to the ... Dee Olsen turned to New Energy Works, after following the ... to design and build their dream vacation home on land ...
(Date:9/30/2014)... Minneapolis, MN (PRWEB) September 30, 2014 ... recognized leader in business technology and services was ... in First Call Effectiveness (FCE) in 2013. This ... devices properly the first time and for an ... longevity. For more than 20 years BEI Services ...
Breaking Medicine News(10 mins):Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 2Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 3Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 4Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 5Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 6Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 2Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 3Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 4Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 5Health News:Nobel Prize For Child Advocates Announces 2014 Health Award Honoree 2Health News:Nobel Prize For Child Advocates Announces 2014 Health Award Honoree 3Health News:Reclaimed Timber Frame Home By New Energy Works Featured in Timber Home Living Magazine 2Health News:Reclaimed Timber Frame Home By New Energy Works Featured in Timber Home Living Magazine 3Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 2Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 3
... suffers collateral damage from blood sugar disease , , FRIDAY, ... cause of heart disease, stroke, blindness, kidney failure and ... quicker than they normally do with age, a new ... in lung function as they grow older, research published ...
... reported study concluded that errant electronic noise from iPods ... didnt sound right to the cardiac electrophysiologists at Childrens ... young adults with heart conditions requiring pacemakers. Many of ... players, and weve never seen any problem, says Charles ...
... G.,Rendell today released the text of his March 27 ... MCare fund assessment payments:, Dear Health Care Provider:, ... state was in a unique,position to extend MCare abatements ... health care for hundreds of thousands of uninsured,Pennsylvanians., ...
... at Catholic Facilities Join Union, LOS ANGELES, ... overwhelming majority of healthcare workers at St. Francis ... Foundation health clinics in,the Sacramento area voted in ... (UHW)., "This victory shows we,re united," said ...
... blood cells could warn doctors early to change treatments ... Temple University think they may have found a blood ... causes AIDS. , The researchers found an increase in ... of human immunodeficiency virus (HIV), according to a study ...
... Health Volunteers,Overseas (HVO) and the American Society of ... the first HVO hematology training program, at,Mulago Hospital ... 1500-bed,facility that serves as Uganda,s national referral, teaching, ... The overall goal of,this program is to improve ...
Cached Medicine News:Health News:Lung Capacity Declines Faster With Diabetes 2Health News:Lung Capacity Declines Faster With Diabetes 3Health News:iPods and similar devices found not to affect pacemaker function 2Health News:Governor Rendell Writes to Physicians to Explain MCare Fund Assessment Deadline 2Health News:Healthcare Workers Across California Vote to Join UHW 2Health News:Biomarker May Signal HIV Progression 2Health News:HVO Launches Hematology Program in Uganda in Partnership with ASH 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: